New drug ATX101 takes first step: safety check in healthy people
NCT ID NCT07107802
First seen Dec 17, 2025 · Last updated Jun 08, 2026 · Updated 28 times
Summary
This early-stage study tested the safety of a new drug called ATX101 in 24 healthy adults aged 18 to 50. Participants received a single dose through a vein, and researchers monitored for side effects and how the drug moved through the body. The goal was not to treat any disease, but to gather essential safety information before future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
BlueClinical Phase I
Porto, 4250-449, Portugal
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.